Schizophrenia Impacts and Treatment Priorities: Results of An Externally-Led Patient-Focused Drug Development Meeting Survey

Faegre Drinker Consulting principal Terry Frangiosa and director of research and strategy Ilse Peterson co-authored an article titled “Schizophrenia Impacts and Treatment Priorities: Results of An Externally-Led Patient-Focused Drug Development Meeting Survey” for Therapeutic Innovation & Regulatory Science.

The article provided an overview of a survey that used data gathered for an Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting led by the schizophrenia community to inform the US Food and Drug Administration. The co-authors discussed how that data informs schizophrenia’s impacts on daily life, reasons for discontinuation of medication, and desired outcomes of future medications.